Accessibility Menu
 
Freeline Therapeutics Plc logo

Freeline Therapeutics Plc

(NASDAQ) FRLN

Current PriceN/A
Market CapN/A
Since IPO (2020)-98%
5 YearN/A
1 Year-20%
1 Month+2%

Freeline Therapeutics Plc Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$622.00K

Net Income (TTM)

$49.93M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

FRLN News

No articles available.

FRLN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Freeline Therapeutics Plc

Industry

Biotechnology

Employees

152

CEO

Michael J. Parini

Headquarters

Stevenage, SG1 2FX, GB

FRLN Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-1%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$1.74M

Operating Income

$98.45M

EBITDA

$97.17M

Operating Cash Flow

$78.22M

Capital Expenditure

$7.01M

Free Cash Flow

$85.24M

Cash & ST Invst.

$47.28M

Total Debt

$5.92M

Freeline Therapeutics Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$5.00K

N/A

Gross Profit

$378.76K

+5.9%

Gross Margin

-75.75%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

152

N/A

Net Income

$12.09M

+18.8%

EBITDA

$11.56M

+48.7%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Net Cash

$25.46M

-52.7%

Accounts Receivable

$2.82M

-4.8%

Inventory

$768.00K

-81.0%

Long Term Debt

$1.70M

-81.2%

Short Term Debt

$2.29M

-20.7%

Return on Assets

-1.03%

N/A

Return on Invested Capital

-1.77%

N/A

Free Cash Flow

$8.68M

+50.0%

Operating Cash Flow

$8.67M

+42.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALLKAllakos Inc.
$0.33+0.22%
SERSerina Therapeutics, Inc.
$2.54+2.42%
ANPCAnPac Bio-Medical Science Co., Ltd.
$4.30-3.15%
LMNLLiminal BioSciences Inc.
$8.50+0.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
TAT&T
$28.31+0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About FRLN

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.